C12N 2760/10023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2760/10023 (Virus like particles [vlp]) appears on 4 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 12
- Assignees
- 8
- Inventors
- 35
- Latest grant
- 7 May 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 3 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Lassa vaccine7 May 2024US 11,976,305 B2Centre National De La Recherche Scientifique
- Modified arenavirus1 Mar 2022US 11,260,090 B2University of Vermont and State Agricultural College
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors8 May 2018US 9,963,718 B2Viratherapeutics GmbH
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors16 May 2017US 9,650,649 B2Viratherapeutics GmbH
- Tri-segmented pichinde viruses as vaccine vectors23 Apr 2026US 2026/0109736 A1Hookipa Biotech GmbH
- Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies6 Mar 2025US 2025/0073324 A1Hookipa Biotech GmbH
- Cancer treatment strategies using arenavirus vectors2 Nov 2023US 2023/0346906 A1Hookipa Biotech GmbH
- Tri-segmented pichinde viruses as vaccine vectors15 Sep 2022US 2022/0289797 A1Hookipa Biotech GmbH
- Lassa vaccine1 Oct 2020US 2020/0308555 A1Centre National De La Recherche Scientifique
Most cited
By later US patents